Biosimilars: Maximizing Adoption
To achieve savings benefits from the coming wave of biosimilars, biosimilars must be adopted by prescribers, members, and payers (through their formulary strategies). While previous...
It’s a Bird! It’s a Plane! No, Just Another Healthcare Disruptor!
As with many things in life, change is challenging, often undetected when it starts, many times mislabeled as an aberration, but always important. As John F. Kennedy once said...
Biosimilars: Payer Decision Making
Once the first Humira biosimilar, Amjevita, launched in the United States in January, payers needed to begin making decisions about coverage not only for Amjevita but for all the other Humira...
Health Insurer Capital: How Much Surplus Should a US Health Insurer Hold?
Health insurers are required to hold minimum levels of surplus each year. However, the exact amount a health insurer chooses to hold can vary significantly from one insurer to the next...
How Many Doctors Does It Take to Make a Healthcare System?
For a healthcare system to run efficiently there is a balance that needs to be found where there is adequate staffing to accommodate the needs of a population. Too much staffing and supply...
Three Reasons to Consult an Actuary
In the world of employee benefits, organizations and brokers often find themselves struggling to get a clear picture of the entire health benefits landscape. For self-funded groups, the challenge lies in managing...
The Financial Impact of Biosimilars
There is a coming wave of changes arriving soon to the pharmacy market in the form of biosimilars. And that coming wave has a big event in 2023: the launch of Humira biosimilars, which...
Provider Contracting Trends – Déjà vu All Over Again
About 30 years ago I met with my then-business partner to think into the future and try to anticipate what we might see in terms of changes in the healthcare system. The results of this challenging process were...
The Big Event: Humira Biosimilar Launches
Today is the day! The Big Event of 2023 is the launch of multiple Humira biosimilars which begins today with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita is the first step in the Big Event...
Biosimilars: The Coming Wave
There is a big wave of changes coming to the pharmacy market. The extent of the impact this wave will bring is not yet fully known, but there are trends we can follow that help predict what this change will look like...